ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · MONDO_0043839

ulcer disease

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. ulcer disease. Diseases, record MONDO_0043839. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0043839

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
ulcer disease
Open Targets
Open Targets ID
MONDO_0043839
Open Targets
Other names
ulcer, ulcers
Open Targets
MeSH
D014456
MeSH
NCI Thesaurus
C3426
NCI Thesaurus
Highest stage of its drugs
Approval, for 15 of its 26 drugs, from DailyMed, PMDA and TTD
Open Targets

Drugs26

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
POLAPREZINCCHEMBL3184454Small moleculeApprovalTTD211Drugs and targets
LANSOPRAZOLECHEMBL480Small moleculeApprovalPMDA200Drugs and targets
COLLAGENASE CLOSTRIDIUM HISTOLYTICUMCHEMBL2108709EnzymeApprovalDailyMed100Drugs and targets
DAPTOMYCINCHEMBL387675Small moleculeApprovalPMDA100Drugs and targets
DIMETHICONECHEMBL2108200ApprovalDailyMed100Drugs and targets
ENPROSTILCHEMBL2104194Small moleculeApprovalTTD100Drugs and targets
ESOMEPRAZOLE MAGNESIUMCHEMBL5314366Small moleculeApprovalPMDA100Drugs and targets
FAMOTIDINECHEMBL902Small moleculeApprovalDailyMed100Drugs and targets
ORNOPROSTILCHEMBL2107020Small moleculeApprovalTTD100Drugs and targets
PLAUNOTOLCHEMBL285815Small moleculeApprovalTTD100Drugs and targets

1 to 10 of 26

See all 26 drugs

Targets35

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
ATP4APotassium-transporting ATPase3Potassium-transporting ATPase inhibitorApprovalhttps://conductscience.org/library/genes/495Drugs and targets
ATP4BPotassium-transporting ATPase3Potassium-transporting ATPase inhibitorApprovalhttps://conductscience.org/library/genes/496Drugs and targets
EDNRAEndothelin receptor, ET-A/ET-B2Endothelin receptor, ET-A/ET-B antagonistPhase 3https://conductscience.org/library/genes/1909Drugs and targets
EDNRBEndothelin receptor, ET-A/ET-B2Endothelin receptor, ET-A/ET-B antagonistPhase 3https://conductscience.org/library/genes/1910Drugs and targets
GUCY1A1Soluble guanylate cyclase2Soluble guanylate cyclase activator; Soluble guanylate cyclase positive allosteric modulatorPhase 2https://conductscience.org/library/genes/2982Drugs and targets
GUCY1A2Soluble guanylate cyclase2Soluble guanylate cyclase activator; Soluble guanylate cyclase positive allosteric modulatorPhase 2https://conductscience.org/library/genes/2977Drugs and targets
GUCY1B1Soluble guanylate cyclase2Soluble guanylate cyclase activator; Soluble guanylate cyclase positive allosteric modulatorPhase 2https://conductscience.org/library/genes/2983Drugs and targets
HRH2Histamine H2 receptor2Histamine H2 receptor antagonistApprovalhttps://conductscience.org/library/genes/3274Drugs and targets
CD274Programmed cell death 1 ligand 11Programmed cell death 1 ligand 1 inhibitorEarly phase 1https://conductscience.org/library/genes/29126Drugs and targets
COL11A1Collagen1Collagen hydrolytic enzymeApprovalhttps://conductscience.org/library/genes/1301Drugs and targets

1 to 10 of 35

See all 35 targets

Trials7

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT01474122Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis PatientsPhase 32652015-01-28Digital UlcersMACITENTANOpen Targets' reading of its recordClinicalTrials.gov
NCT01309802A Two-Part Study of BOTOX® Therapy for Ischemic DigitsPhase 2482017-06-02Raynaud's DiseaseBOTULINUM TOXIN TYPE AOpen Targets' reading of its recordClinicalTrials.gov
NCT02915835Riociguat in Scleroderma Associated Digital UlcersPhase 2172019-09-24Scleroderma, Digital UlcersRIOCIGUATOpen Targets' reading of its recordClinicalTrials.gov
NCT00077584Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Patients With SclerodermaPhase 3188Digital Ulcers, Systemic SclerosisBOSENTANOpen Targets' reading of its recordClinicalTrials.gov
NCT02243618The Effect of Proton Pump Inhibitor and Polaprezinc Combination Therapy for Healing of Endoscopic Submucosal Dissection-induced UlcerNot applicable153Gastric Adenoma, Early Gastric CancerPOLAPREZINC, REBAMIPIDEIts record names the diseaseClinicalTrials.gov
NCT00771368Reduction of Bacteria in MRSA Positive UlcersPhase 1/220Leg Ulcer, Pressure UlcerNITRIC OXIDEIts record names the diseaseClinicalTrials.gov
NCT04800562A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis LipoidicaPhase 24Necrobiosis LipoidicaPCS-499Open Targets' reading of its recordClinicalTrials.gov

Comparisons in its trials18

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
Onabotulinum Toxin Type-A vs Placebo: deaths from any cause0 of 230 of 2548NCT01309802Trial comparisons
Onabotulinum Toxin Type-A vs Placebo: serious adverse events2 of 235 of 2548NCT01309802Trial comparisons
Riociguat vs Placebo: Proportion of Participants Who Experience Digital Ischemia Requiring Intravenous Prostacyclin or Digital Gangrene or Amputation During the Trial.0 of 91 of 817NCT02915835Trial comparisons
Riociguat vs Placebo: deaths from any cause0 of 90 of 817NCT02915835Trial comparisons
Riociguat vs Placebo: Proportion of Participants Who Develop Osteomyelitis During The Trial0 of 90 of 817NCT02915835Trial comparisons
Riociguat vs Placebo: serious adverse events3 of 91 of 817NCT02915835Trial comparisons
Riociguat vs Placebo: Proportion of Participants Who Develop Pressure Ulcers at Proximal Interphalangeal (PIP) Location Over the Course of the Double-blind Period.1 of 82 of 816NCT02915835Trial comparisons
Riociguat vs Placebo: Proportion of Participants With New Active and Indeterminate DU(s) Over the Course of the Double-blind Period3 of 84 of 816NCT02915835Trial comparisons
Riociguat vs Placebo: Proportion of Participants With Healing of Their Cardinal DU by Week 164 of 86 of 816NCT02915835Trial comparisons
Riociguat vs Placebo: Proportion of Participants Who Develop Pressure Ulcers at Distal Interphalangeal (DIP) Location Over the Course of the Double-blind Period.0 of 81 of 816NCT02915835Trial comparisons

1 to 10 of 18

See all 18 comparisons in its trials

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
27163986RESULT1PubMed
20805294RESULT1PubMed
33765691DERIVED1PubMed
31481106DERIVED1PubMed

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0043839

GET https://conductscience.org/api/diseases/v1/MONDO_0043839/drugs?page=2

API referenceFor AI assistants